York Capital Management Global Advisors’s AstraZeneca AZN Stock Holding History

York Capital Management Global Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-716,564	Closed	-$57.9M	–	55
2019 Q1	$57.9M	Sell	716,564 -209,745	-23%	-$16.5M	2.6%	14
2018 Q4	$70.4M	Sell	926,309 -145,215	-14%	-$11.3M	4.27%	8
2018 Q3	$84.8M	Sell	1,071,524 -176,369	-14%	-$13.3M	2.68%	13
2018 Q2	$87.6M	Buy	1,247,893 +439,461	+54%	+$31.6M	2.13%	12
2018 Q1	$56.5M	Buy	+808,432	New	+$56M	1.27%	21
2014 Q4	–	Sell	-528,688	Closed	-$37.8M	–	108
2014 Q3	$37.8M	Sell	528,688 -1,093,130	-67%	-$80M	0.38%	50
2014 Q2	$121M	Buy	+1,621,818	New	+$117M	1.2%	31

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

York Capital Management Global Advisors's AZN Position: Q2 2019 in Review

York Capital Management Global Advisors sold out of AstraZeneca (AZN) in Q2 2019, closing a stake of 716,564 shares — an estimated $57.9M sold.

York Capital Management Global Advisors first reported a position in AZN in Q2 2014 and held it in 7 quarters. The position peaked at $121M in Q2 2014. 546 funds tracked by Wall St. Rank hold AZN as of Q2 2019.

York Capital Management Global Advisors reported no remaining AstraZeneca position as of Q2 2019 after selling out during the quarter.
York Capital Management Global Advisors sold 716,564 AstraZeneca shares in Q2 2019, an estimated $57.9M.
York Capital Management Global Advisors first reported a position in AstraZeneca in Q2 2014 and held it in 7 quarters.
York Capital Management Global Advisors's AstraZeneca position peaked at $121M in Q2 2014.
546 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2019.

Based on York Capital Management Global Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.